This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsDiurnal Group (DNL) 주식 개요Diurnal Group plc operates as a specialty pharma company worldwide. 자세히 보기DNL 펀더멘털 분석스노우플레이크 점수가치 평가3/6미래 성장2/6과거 실적0/6재무 건전성5/6배당0/6강점수익은 연간 62.15% 증가할 것으로 예상됩니다.위험 분석지난 3개월 동안 주가 변동성이 UK 시장과 비교했을 때 매우 높았습니다.cash runway 경력이 1년 미만입니다.의미 있는 시가총액이 없습니다(£48M)지난 1년 동안 주주가 희석되었습니다.모든 위험 점검 보기DNL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW484,962 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA484,962 investors already sharing narrativesYour Fair ValueUK£Current PriceUK£0.27해당 없음내재 할인율Est. Revenue$PastFuture-26m53m2016201920222025202620282031Revenue UK£52.5mEarnings UK£9.3mAdvancedSet Fair ValueView all narrativesDiurnal Group plc 경쟁사Tissue Regenix GroupSymbol: AIM:TRXMarket cap: UK£5.2mArecor TherapeuticsSymbol: AIM:ARECMarket cap: UK£21.7mDestiny PharmaSymbol: AIM:DESTMarket cap: UK£4.5mOptiBiotix HealthSymbol: AIM:OPTIMarket cap: UK£5.9m가격 이력 및 성과Diurnal Group 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가UK£0.2752주 최고가UK£0.6852주 최저가UK£0.095베타0.351개월 변동0.55%3개월 변동180.00%1년 변동-54.65%3년 변동-14.69%5년 변동-80.84%IPO 이후 변동-82.16%최근 뉴스 및 업데이트분석 기사 • Aug 13Diurnal Group (LON:DNL) Will Have To Spend Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Breakeven Date Change • Jul 01Forecast to breakeven in 2025The 4 analysts covering Diurnal Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of UK£7.56m in 2025. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Price Target Changed • Apr 27Price target decreased to UK£1.24Down from UK£1.52, the current price target is an average from 5 analysts. New target price is 762% above last closing price of UK£0.14. Stock is down 79% over the past year. The company is forecast to post a net loss per share of UK£0.10 next year compared to a net loss per share of UK£0.073 last year.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Jean-Michel Yves Cossery was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Price Target Changed • Apr 01Price target decreased to UK£1.24Down from UK£1.60, the current price target is an average from 5 analysts. New target price is 673% above last closing price of UK£0.16. Stock is down 81% over the past year. The company is forecast to post a net loss per share of UK£0.095 next year compared to a net loss per share of UK£0.073 last year.Price Target Changed • Mar 23Price target decreased to UK£1.52Down from UK£1.66, the current price target is an average from 5 analysts. New target price is 883% above last closing price of UK£0.15. Stock is down 78% over the past year. The company is forecast to post a net loss per share of UK£0.091 next year compared to a net loss per share of UK£0.073 last year.더 많은 업데이트 보기Recent updates분석 기사 • Aug 13Diurnal Group (LON:DNL) Will Have To Spend Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Breakeven Date Change • Jul 01Forecast to breakeven in 2025The 4 analysts covering Diurnal Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of UK£7.56m in 2025. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Price Target Changed • Apr 27Price target decreased to UK£1.24Down from UK£1.52, the current price target is an average from 5 analysts. New target price is 762% above last closing price of UK£0.14. Stock is down 79% over the past year. The company is forecast to post a net loss per share of UK£0.10 next year compared to a net loss per share of UK£0.073 last year.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Jean-Michel Yves Cossery was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Price Target Changed • Apr 01Price target decreased to UK£1.24Down from UK£1.60, the current price target is an average from 5 analysts. New target price is 673% above last closing price of UK£0.16. Stock is down 81% over the past year. The company is forecast to post a net loss per share of UK£0.095 next year compared to a net loss per share of UK£0.073 last year.Price Target Changed • Mar 23Price target decreased to UK£1.52Down from UK£1.66, the current price target is an average from 5 analysts. New target price is 883% above last closing price of UK£0.15. Stock is down 78% over the past year. The company is forecast to post a net loss per share of UK£0.091 next year compared to a net loss per share of UK£0.073 last year.Breakeven Date Change • Jan 18No longer forecast to breakevenThe 5 analysts covering Diurnal Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of UK£12.4m in 2024. New consensus forecast suggests the company will make a loss of UK£18.0m in 2024.Breakeven Date Change • Dec 15No longer forecast to breakevenThe 5 analysts covering Diurnal Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of UK£12.4m in 2024. New consensus forecast suggests the company will make a loss of UK£12.0m in 2024.Price Target Changed • Nov 27Price target decreased to UK£1.66Down from UK£1.87, the current price target is an average from 4 analysts. New target price is 184% above last closing price of UK£0.58. Stock is up 17% over the past year. The company is forecast to post a net loss per share of UK£0.085 next year compared to a net loss per share of UK£0.073 last year.분석 기사 • Nov 13Shareholders May Not Be So Generous With Diurnal Group plc's (LON:DNL) CEO Compensation And Here's WhyCEO Martin Whitaker has done a decent job of delivering relatively good performance at Diurnal Group plc ( LON:DNL...Reported Earnings • Sep 15Full year 2021 earnings released: UK£0.073 loss per share (vs UK£0.043 loss in FY 2020)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: UK£4.37m (down 31% from FY 2020). Net loss: UK£10.0m (loss widened 147% from FY 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Jul 16CFO, Company Secretary & Director recently sold UK£67k worth of stockOn the 13th of July, Richard Bungay sold around 106k shares on-market at roughly UK£0.63 per share. This was the largest sale by an insider in the last 3 months. Richard has been a seller over the last 12 months, reducing personal holdings by UK£62k.Breakeven Date Change • Jul 02Forecast to breakeven in 2024The 4 analysts covering Diurnal Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of UK£40.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Price Target Changed • Mar 26Price target increased to UK£1.25Up from UK£0.94, the current price target is an average from 4 analysts. New target price is 40% above last closing price of UK£0.89. Stock is up 178% over the past year.Major Estimate Revision • Mar 26Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from UK£3.06m to UK£3.53m. EPS estimate unchanged from -UK£0.086 at last update. Biotechs industry in the United Kingdom expected to see average net income growth of 2.3% next year. Consensus price target of UK£0.97 unchanged from last update. Share price rose 38% to UK£0.89 over the past week.Is New 90 Day High Low • Mar 15New 90-day high: UK£0.67The company is up 38% from a price of UK£0.48 on 15 December 2020. Outperformed the British market which is up 5.0% over the last 90 days. Exceeded the Biotechs industry, which is up 24% over the same period.Reported Earnings • Feb 25First half 2021 earnings released: UK£0.037 loss per share (vs UK£0.047 loss in 1H 2020)The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: UK£1.21m (up 5.8% from 1H 2020). Net loss: UK£4.66m (loss widened 16% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.분석 기사 • Feb 25Companies Like Diurnal Group (LON:DNL) Can Afford To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...분석 기사 • Feb 04What Can We Learn About Diurnal Group's (LON:DNL) CEO Compensation?Martin Whitaker is the CEO of Diurnal Group plc ( LON:DNL ), and in this article, we analyze the executive's...Major Estimate Revision • Jan 18Analysts update estimatesThe 2021 consensus revenue estimate was lowered from UK£5.62m to UK£4.76m. Earning per share (EPS) estimate was unchanged from the last update at -UK£0.066. The Biotechs industry in the United Kingdom is expected to see an average net income growth of 4.1% next year. The consensus price target of UK£0.94 was unchanged from the last update. Share price stayed mostly flat at UK£0.62 over the past week.분석 기사 • Jan 14Diurnal Group plc (LON:DNL): When Will It Breakeven?Diurnal Group plc ( LON:DNL ) is possibly approaching a major achievement in its business, so we would like to shine...Is New 90 Day High Low • Jan 13New 90-day high: UK£0.66The company is up 6.0% from its price of UK£0.62 on 15 October 2020. The British market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.54 per share.분석 기사 • Dec 25Diurnal Group (LON:DNL) Shareholders Have Enjoyed A 88% Share Price GainWhile Diurnal Group plc ( LON:DNL ) shareholders are probably generally happy, the stock hasn't had particularly good...분석 기사 • Dec 02Estimating The Fair Value Of Diurnal Group plc (LON:DNL)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Diurnal Group plc...Price Target Changed • Nov 20Price target lowered to UK£0.88Down from UK£0.96, the current price target is an average from 2 analysts. The new target price is 68% above the current share price of UK£0.53. As of last close, the stock is up 59% over the past year.Is New 90 Day High Low • Nov 18New 90-day low: UK£0.53The company is down 9.0% from its price of UK£0.58 on 20 August 2020. The British market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.44 per share.Reported Earnings • Oct 10Full year earnings released - UK£0.043 loss per shareOver the last 12 months the company has reported total losses of UK£4.07m, with losses narrowing by 67% from the prior year. Total revenue was UK£6.31m over the last 12 months, up by UK£5.26m from the prior year.Analyst Estimate Surprise Post Earnings • Oct 10Annual earnings released: Revenue and earnings beat expectationsAnnual revenue exceeded analyst estimates by 164% at UK£6.31m. Earnings per share (EPS) also surpassed analyst estimates by 34% at -UK£0.043. Revenue is expected to shrink by 3.7% over the next year, compared to a 50% growth forecast for the Biotechs industry in the United Kingdom.Major Estimate Revision • Oct 01Analysts increase revenue estimates to UK£6.08mThe 2021 consensus revenue estimate increased from UK£4.70m. Earning per share (EPS) estimate also saw an improvement, with analysts raising their estimates from -UK£0.044 to -UK£0.032 for the same period. The Biotechs industry in the United Kingdom is expected to see an average net income growth of 11% next year. The consensus price target increased from UK£0.84 to UK£0.96. Share price is down by 14% to UK£0.65 over the past week.Price Target Changed • Sep 30Price target raised to UK£0.96Up from UK£0.84, the current price target is an average from 2 analysts. The new target price is 49% above the current share price of UK£0.65. As of last close, the stock is up 164% over the past year.Is New 90 Day High Low • Sep 19New 90-day high: UK£0.65The company is up 81% from its price of UK£0.36 on 19 June 2020. The British market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.주주 수익률DNLGB BiotechsGB 시장7D0%-1.2%0.5%1Y-54.7%-4.0%18.8%전체 주주 수익률 보기수익률 대 산업: DNL은 지난 1년 동안 -4%의 수익을 기록한 UK Biotechs 산업보다 저조한 성과를 냈습니다.수익률 대 시장: DNL은 지난 1년 동안 18.8%를 기록한 UK 시장보다 저조한 성과를 냈습니다.주가 변동성Is DNL's price volatile compared to industry and market?DNL volatilityDNL Average Weekly Movement38.5%Biotechs Industry Average Movement6.9%Market Average Movement5.1%10% most volatile stocks in GB Market10.4%10% least volatile stocks in GB Market2.7%안정적인 주가: DNL의 주가는 지난 3개월 동안 UK 시장보다 변동성이 컸습니다.시간에 따른 변동성: DNL의 주간 변동성은 지난 1년간 21%에서 39%로 증가했습니다.회사 소개설립직원 수CEO웹사이트201533Richard Bungaywww.diurnal.co.uk더 보기Diurnal Group plc 기초 지표 요약Diurnal Group의 순이익과 매출은 시가총액과 어떻게 비교됩니까?DNL 기초 통계시가총액UK£47.74m순이익 (TTM)-UK£16.57m매출 (TTM)UK£4.68m10.2x주가매출비율(P/S)-2.9x주가수익비율(P/E)DNL는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표DNL 손익계산서 (TTM)매출UK£4.68m매출원가UK£1.02m총이익UK£3.66m기타 비용UK£20.23m순이익-UK£16.57m최근 보고된 실적Jun 30, 2022다음 실적 발표일해당 없음주당순이익(EPS)-0.095총이익률78.16%순이익률-353.76%부채/자본 비율0.0%DNL의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2022/11/02 00:42종가2022/11/01 00:00수익2022/06/30연간 수익2022/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Diurnal Group plc는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Michael FosterHardman & Co.James OrsborneStifel, Equities Research
분석 기사 • Aug 13Diurnal Group (LON:DNL) Will Have To Spend Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Breakeven Date Change • Jul 01Forecast to breakeven in 2025The 4 analysts covering Diurnal Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of UK£7.56m in 2025. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Price Target Changed • Apr 27Price target decreased to UK£1.24Down from UK£1.52, the current price target is an average from 5 analysts. New target price is 762% above last closing price of UK£0.14. Stock is down 79% over the past year. The company is forecast to post a net loss per share of UK£0.10 next year compared to a net loss per share of UK£0.073 last year.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Jean-Michel Yves Cossery was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Price Target Changed • Apr 01Price target decreased to UK£1.24Down from UK£1.60, the current price target is an average from 5 analysts. New target price is 673% above last closing price of UK£0.16. Stock is down 81% over the past year. The company is forecast to post a net loss per share of UK£0.095 next year compared to a net loss per share of UK£0.073 last year.
Price Target Changed • Mar 23Price target decreased to UK£1.52Down from UK£1.66, the current price target is an average from 5 analysts. New target price is 883% above last closing price of UK£0.15. Stock is down 78% over the past year. The company is forecast to post a net loss per share of UK£0.091 next year compared to a net loss per share of UK£0.073 last year.
분석 기사 • Aug 13Diurnal Group (LON:DNL) Will Have To Spend Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Breakeven Date Change • Jul 01Forecast to breakeven in 2025The 4 analysts covering Diurnal Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of UK£7.56m in 2025. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Price Target Changed • Apr 27Price target decreased to UK£1.24Down from UK£1.52, the current price target is an average from 5 analysts. New target price is 762% above last closing price of UK£0.14. Stock is down 79% over the past year. The company is forecast to post a net loss per share of UK£0.10 next year compared to a net loss per share of UK£0.073 last year.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Jean-Michel Yves Cossery was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Price Target Changed • Apr 01Price target decreased to UK£1.24Down from UK£1.60, the current price target is an average from 5 analysts. New target price is 673% above last closing price of UK£0.16. Stock is down 81% over the past year. The company is forecast to post a net loss per share of UK£0.095 next year compared to a net loss per share of UK£0.073 last year.
Price Target Changed • Mar 23Price target decreased to UK£1.52Down from UK£1.66, the current price target is an average from 5 analysts. New target price is 883% above last closing price of UK£0.15. Stock is down 78% over the past year. The company is forecast to post a net loss per share of UK£0.091 next year compared to a net loss per share of UK£0.073 last year.
Breakeven Date Change • Jan 18No longer forecast to breakevenThe 5 analysts covering Diurnal Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of UK£12.4m in 2024. New consensus forecast suggests the company will make a loss of UK£18.0m in 2024.
Breakeven Date Change • Dec 15No longer forecast to breakevenThe 5 analysts covering Diurnal Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of UK£12.4m in 2024. New consensus forecast suggests the company will make a loss of UK£12.0m in 2024.
Price Target Changed • Nov 27Price target decreased to UK£1.66Down from UK£1.87, the current price target is an average from 4 analysts. New target price is 184% above last closing price of UK£0.58. Stock is up 17% over the past year. The company is forecast to post a net loss per share of UK£0.085 next year compared to a net loss per share of UK£0.073 last year.
분석 기사 • Nov 13Shareholders May Not Be So Generous With Diurnal Group plc's (LON:DNL) CEO Compensation And Here's WhyCEO Martin Whitaker has done a decent job of delivering relatively good performance at Diurnal Group plc ( LON:DNL...
Reported Earnings • Sep 15Full year 2021 earnings released: UK£0.073 loss per share (vs UK£0.043 loss in FY 2020)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: UK£4.37m (down 31% from FY 2020). Net loss: UK£10.0m (loss widened 147% from FY 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Jul 16CFO, Company Secretary & Director recently sold UK£67k worth of stockOn the 13th of July, Richard Bungay sold around 106k shares on-market at roughly UK£0.63 per share. This was the largest sale by an insider in the last 3 months. Richard has been a seller over the last 12 months, reducing personal holdings by UK£62k.
Breakeven Date Change • Jul 02Forecast to breakeven in 2024The 4 analysts covering Diurnal Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of UK£40.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Price Target Changed • Mar 26Price target increased to UK£1.25Up from UK£0.94, the current price target is an average from 4 analysts. New target price is 40% above last closing price of UK£0.89. Stock is up 178% over the past year.
Major Estimate Revision • Mar 26Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from UK£3.06m to UK£3.53m. EPS estimate unchanged from -UK£0.086 at last update. Biotechs industry in the United Kingdom expected to see average net income growth of 2.3% next year. Consensus price target of UK£0.97 unchanged from last update. Share price rose 38% to UK£0.89 over the past week.
Is New 90 Day High Low • Mar 15New 90-day high: UK£0.67The company is up 38% from a price of UK£0.48 on 15 December 2020. Outperformed the British market which is up 5.0% over the last 90 days. Exceeded the Biotechs industry, which is up 24% over the same period.
Reported Earnings • Feb 25First half 2021 earnings released: UK£0.037 loss per share (vs UK£0.047 loss in 1H 2020)The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: UK£1.21m (up 5.8% from 1H 2020). Net loss: UK£4.66m (loss widened 16% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
분석 기사 • Feb 25Companies Like Diurnal Group (LON:DNL) Can Afford To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
분석 기사 • Feb 04What Can We Learn About Diurnal Group's (LON:DNL) CEO Compensation?Martin Whitaker is the CEO of Diurnal Group plc ( LON:DNL ), and in this article, we analyze the executive's...
Major Estimate Revision • Jan 18Analysts update estimatesThe 2021 consensus revenue estimate was lowered from UK£5.62m to UK£4.76m. Earning per share (EPS) estimate was unchanged from the last update at -UK£0.066. The Biotechs industry in the United Kingdom is expected to see an average net income growth of 4.1% next year. The consensus price target of UK£0.94 was unchanged from the last update. Share price stayed mostly flat at UK£0.62 over the past week.
분석 기사 • Jan 14Diurnal Group plc (LON:DNL): When Will It Breakeven?Diurnal Group plc ( LON:DNL ) is possibly approaching a major achievement in its business, so we would like to shine...
Is New 90 Day High Low • Jan 13New 90-day high: UK£0.66The company is up 6.0% from its price of UK£0.62 on 15 October 2020. The British market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.54 per share.
분석 기사 • Dec 25Diurnal Group (LON:DNL) Shareholders Have Enjoyed A 88% Share Price GainWhile Diurnal Group plc ( LON:DNL ) shareholders are probably generally happy, the stock hasn't had particularly good...
분석 기사 • Dec 02Estimating The Fair Value Of Diurnal Group plc (LON:DNL)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Diurnal Group plc...
Price Target Changed • Nov 20Price target lowered to UK£0.88Down from UK£0.96, the current price target is an average from 2 analysts. The new target price is 68% above the current share price of UK£0.53. As of last close, the stock is up 59% over the past year.
Is New 90 Day High Low • Nov 18New 90-day low: UK£0.53The company is down 9.0% from its price of UK£0.58 on 20 August 2020. The British market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.44 per share.
Reported Earnings • Oct 10Full year earnings released - UK£0.043 loss per shareOver the last 12 months the company has reported total losses of UK£4.07m, with losses narrowing by 67% from the prior year. Total revenue was UK£6.31m over the last 12 months, up by UK£5.26m from the prior year.
Analyst Estimate Surprise Post Earnings • Oct 10Annual earnings released: Revenue and earnings beat expectationsAnnual revenue exceeded analyst estimates by 164% at UK£6.31m. Earnings per share (EPS) also surpassed analyst estimates by 34% at -UK£0.043. Revenue is expected to shrink by 3.7% over the next year, compared to a 50% growth forecast for the Biotechs industry in the United Kingdom.
Major Estimate Revision • Oct 01Analysts increase revenue estimates to UK£6.08mThe 2021 consensus revenue estimate increased from UK£4.70m. Earning per share (EPS) estimate also saw an improvement, with analysts raising their estimates from -UK£0.044 to -UK£0.032 for the same period. The Biotechs industry in the United Kingdom is expected to see an average net income growth of 11% next year. The consensus price target increased from UK£0.84 to UK£0.96. Share price is down by 14% to UK£0.65 over the past week.
Price Target Changed • Sep 30Price target raised to UK£0.96Up from UK£0.84, the current price target is an average from 2 analysts. The new target price is 49% above the current share price of UK£0.65. As of last close, the stock is up 164% over the past year.
Is New 90 Day High Low • Sep 19New 90-day high: UK£0.65The company is up 81% from its price of UK£0.36 on 19 June 2020. The British market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
